Tonix Pharmaceuticals Holding Corp. - Common Stock (TNXP)
0.4125
+0.0325 (8.55%)
Tonix Pharmaceuticals Holdings is a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system disorders and other serious medical conditions
The company is dedicated to advancing its pipeline of product candidates, which include treatments for conditions such as migraines, post-traumatic stress disorder, and various infectious diseases. By leveraging its expertise in drug development and utilizing strategic collaborations, Tonix aims to bring novel treatment options to market that address unmet medical needs and improve patient outcomes.
Stay updated with the latest market activity on Thursday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
Tonix Pharmaceuticals Holding Corp (NASDAQTNXP) shares are trading lower Tuesday after initially jumping after the company announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for TNX-102 SL, a 5.6 mg non-opioid. Here's what you need to know.
Tonix Pharmaceuticals shares are trading higher by 8% during Tuesday's session. The company secured a $34 million DOD research collaboration contract with X-Chem.
AI Security, “Netflix of China”, Healthcare Breakthroughs, Pure Play on $31 Billion Watch Market: iQIYI, TNXP, REGRF, AITX; Leaders Report Latest Advances
